Earnings Call · Q2 FY2021·2021-08-11

Q2 21EPS -7.14%·Rev n/aQ1 21EPS -1.92%·Rev n/aQ4 20EPS -36.84%·Rev n/aQ3 20EPS -5.00%·Rev n/a⚠ consensus missing

Revolution Medicines, Inc. RVMD

Peg Horn — Investor Relations

Dr. Mark Goldsmith — Chairman and Chief Executive Officer

Dr. Steve Kelsey — President Research and Development

Jack Anders — Senior Vice President of Finance

−0.8%1d on move date−1.1% vs SPY3d−5.8%5d−2.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RVMD calls or request research access.

More RVMD calls Browse calls Request research access